FR3060389B1 - Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites - Google Patents
Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites Download PDFInfo
- Publication number
- FR3060389B1 FR3060389B1 FR1662926A FR1662926A FR3060389B1 FR 3060389 B1 FR3060389 B1 FR 3060389B1 FR 1662926 A FR1662926 A FR 1662926A FR 1662926 A FR1662926 A FR 1662926A FR 3060389 B1 FR3060389 B1 FR 3060389B1
- Authority
- FR
- France
- Prior art keywords
- enrobe
- metabolites
- ulipristal acetate
- tablet
- ulipristal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002207 metabolite Substances 0.000 title abstract 2
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 title abstract 2
- 229960000499 ulipristal acetate Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
La présente invention a pour objet un comprimé enrobé comprenant de l'ulipristal acétate ou un de ses métabolites en tant que principe actif et les utilisations contraceptives et thérapeutiques dudit comprimé.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1662926A FR3060389B1 (fr) | 2016-12-20 | 2016-12-20 | Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites |
PCT/FR2017/053735 WO2018115743A1 (fr) | 2016-12-20 | 2017-12-20 | Comprime enrobe comprenant de l'ulipristal acétate ou un de ses métabolites |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1662926A FR3060389B1 (fr) | 2016-12-20 | 2016-12-20 | Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites |
FR1662926 | 2016-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3060389A1 FR3060389A1 (fr) | 2018-06-22 |
FR3060389B1 true FR3060389B1 (fr) | 2019-05-31 |
Family
ID=58501547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1662926A Active FR3060389B1 (fr) | 2016-12-20 | 2016-12-20 | Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR3060389B1 (fr) |
WO (1) | WO2018115743A1 (fr) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
ES2212912B1 (es) | 2003-01-22 | 2005-10-01 | Crystal Pharma, S.A. | Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona. |
US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
EP2419108B1 (fr) | 2009-04-14 | 2016-08-17 | Laboratoire HRA Pharma | Methode de contraception à la demande |
CN102727457B (zh) * | 2011-04-08 | 2014-05-28 | 华润紫竹药业有限公司 | 稳定的醋酸优力司特制剂 |
FR2997627B1 (fr) | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant de l'ulipristal acetate |
FR2997628B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone |
FR2999081B1 (fr) | 2012-12-06 | 2015-02-27 | Hra Pharma Lab | Dispersion solide d'un modulateur selectif du recepteur a la progesterone |
-
2016
- 2016-12-20 FR FR1662926A patent/FR3060389B1/fr active Active
-
2017
- 2017-12-20 WO PCT/FR2017/053735 patent/WO2018115743A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
FR3060389A1 (fr) | 2018-06-22 |
WO2018115743A1 (fr) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49043A (fr) | Formulation stable d'anticorps | |
MA43709A (fr) | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations | |
BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
MA38960A1 (fr) | Formulations d'anticorps anti-pdl1 | |
BR112019025049A2 (pt) | Anéis 6- 5 fundidos como inibidores de c5a | |
MA45450B1 (fr) | Formulations d'anticorps anti-cd19 | |
FR3021970B1 (fr) | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs | |
MX2022001146A (es) | Formulaciones de anticuerpos anti-pvrig y sus usos. | |
AR104257A1 (es) | Tableta de ribociclib | |
BR112017014376A2 (pt) | formulação aquosa estável de anticorpos antifator de crescimento endotelial vascular (vegf) e uso | |
MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
FR3058059B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
MA54052A (fr) | Formulation d'anticorps | |
PH12019502676A1 (en) | Moisturizing topical preparation | |
MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
MA55033A (fr) | Formulation d'anticorps thérapeutique | |
MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
MX2019002104A (es) | Compuesto de 3-piridiloxifenildihidrouracilo y su uso. | |
MA45718A (fr) | Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées | |
FR3060389B1 (fr) | Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites | |
MA54222A (fr) | Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées | |
MA54095A (fr) | Formulations pharmaceutiques aqueuses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20180622 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |